Is Seres Therapeutics Still A Buy After Disappointing SER-287 Topline Results?
Seres Therapeutics (NASDAQ: MCRB) is a microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that interact with host cells and tissues to treat disease.
Seres SER-109 is the companys lead clinical candidate and…
